New west nile vaccine enters first human tests
NCT ID NCT06745921
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 8 times
Summary
This early-stage trial is testing a new vaccine called HydroVax-001B WNV to see if it is safe and triggers an immune response against West Nile virus, a mosquito-borne disease. About 30 healthy adults aged 18 to 49 will receive either the vaccine or a placebo. The study will compare two different doses and monitor for side effects and immune reactions over several months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HydroVax-001B WNV vaccine (inactivated West Nile virus)
- What this could lead to
- If successful, this could lead to a safe and effective vaccine to prevent West Nile virus infection.
- What could go wrong
- This is a very early phase 1 trial with only 30 participants, so it is too soon to know if the vaccine works or is safe for the general population.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WEST NILE VIRAL INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Saint Louis University Center for Vaccine Development
St Louis, Missouri, 63104-1015, United States